Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

The financial data indicates notable fluctuations in key income metrics over the five-year period analyzed. Net income experienced a substantial increase from 3,513,200 thousand US dollars in 2020 to a peak of 8,075,300 thousand US dollars in 2021, representing more than double the amount in one year. However, this was followed by a significant decline to 4,338,400 thousand in 2022 and a further dip to 3,953,600 thousand in 2023. The net income rebounded somewhat in 2024, reaching 4,412,600 thousand US dollars, though it remained below the 2021 peak.

Unrealized gains and losses on debt securities exhibited considerable volatility. The value shifted from a positive 9,100 thousand US dollars in 2020 to negative 56,400 thousand in 2021, then further declined to negative 213,600 thousand in 2022. This negative trend reversed in 2023, with a turnaround to a positive 158,200 thousand, followed by a reduction to 73,600 thousand in 2024. Such swings suggest sensitivity to market conditions impacting debt securities valuation during these years.

The gain or loss on foreign currency translation was notably minimal and only recorded in the last two years, showing small negative values of -300 thousand in 2023 and -600 thousand in 2024. These figures signal minor foreign exchange impacts on financial results in recent periods.

Unrealized gains or losses on cash flow hedges remained relatively small, fluctuating between -900 thousand in 2020 to positive 900 and 1,000 thousand in 2021 and 2022 respectively. No data is available for 2023 and 2024, which limits trend assessment for these years.

Other comprehensive income (loss), net of tax, followed a trend broadly similar to unrealized gains (losses) on debt securities, moving from a positive 8,200 thousand in 2020 to a sizeable negative 55,500 thousand in 2021 and an even larger negative 212,600 thousand in 2022. There was a recovery in subsequent years with positive figures of 157,900 thousand in 2023 and 73,000 thousand in 2024. This reflects the impact of market-related items on comprehensive income streams.

Comprehensive income mirrored the fluctuations in net income and other comprehensive income. It increased sharply to 8,019,800 thousand in 2021, then declined to 4,125,800 thousand in 2022 and 4,111,500 thousand in 2023. The figure rose again to 4,485,600 thousand in 2024. The pattern highlights the influence of both net income performance and comprehensive income components on overall financial outcomes.

Summary of financial trends:

- Net income showed a strong peak in 2021, followed by a decline and partial recovery by 2024.

- Unrealized gains/losses on debt securities demonstrated marked volatility, with negative impacts in 2021-2022 reversing thereafter.

- Foreign currency translation losses appeared minor and only in the last two years, indicating limited currency impact.

- Cash flow hedges were stable but small in effect, with data incomplete in the final two years.

- Other comprehensive income losses coincided with debt securities’ unrealized losses, with recovery post-2022.

- Comprehensive income largely tracked net income patterns, influenced by both realized and unrealized components.